Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines

Background: Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the Australian Government Therapeutic Goods Administration (TGA) amended the indication to restrict use in BPSD to patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalisch Ellett, Lisa M, Moffat, Anna K, Gadzhanova, Svetla, Pratt, Nicole L, Apajee, Jemisha, Woodward, Michael, Roughead, Elizabeth E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789876/
https://www.ncbi.nlm.nih.gov/pubmed/31336574
http://dx.doi.org/10.3390/pharmacy7030100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789876/
https://www.ncbi.nlm.nih.gov/pubmed/31336574
http://dx.doi.org/10.3390/pharmacy7030100

Ejemplares similares